🔎 Trials Near Me

Почетна › Рак јајника › Охајо

Kliničke studije za Рак јајника u državi Охајо

68 studija za Рак јајника traži učesnike na lokacijama u državi Охајо.

Gradovi u državi Охајо

Zvanični tekst studije (na engleskom)

Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity

  • Ohio State University Comprehensive Cancer Center, Columbus
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 13. 11. 2026. · NCT07001748

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

  • OhioHealth O'Bleness Hospital, Athens
  • UH Seidman Cancer Center at UH Avon Health Center, Avon
  • UHHS-Chagrin Highlands Medical Center, Beachwood
  • и још 41
Тражи се учесникФаза 2
Сви узрасти · Оба пола · Ажурирано 12. 11. 2026. · NCT05564377

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

  • University of Cincinnati Medical Center ( Site 0090), Cincinnati
  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0054), Columbus
Тражи се учесникФаза 3
Узраст 18 и старији · Жене · Ажурирано 10. 11. 2026. · NCT06824467

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

  • University of Cincinnati Medical Center ( Site 0042), Cincinnati
  • The Ohio State University ( Site 0005), Hilliard
Тражи се учесникФаза 3
Узраст 18 и старији · Жене · Ажурирано 10. 11. 2026. · NCT07318558

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

  • OhioHealth O'Bleness Hospital, Athens
  • UHHS-Chagrin Highlands Medical Center, Beachwood
  • Geauga Hospital, Chardon
  • и још 26
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 9. 11. 2026. · NCT06580314

A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression

  • Site 0108, Columbus
Тражи се учесникФаза 3
Узраст 18 и старији · Жене · Ажурирано 9. 11. 2026. · NCT07546500

Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer

  • Research Site, Cleveland
Тражи се учесникФаза 3
Узраст 18 и старији · Жене · Ажурирано 6. 11. 2026. · NCT07851025

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

  • The Ohio State University Comprehensive Cancer Center, Hilliard
Тражи се учесникФаза 2
Узраст 18 и старији · Жене · Ажурирано 6. 11. 2026. · NCT06787612

A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer

  • Aultman Alliance Community Hospital, Alliance
  • OhioHealth O'Bleness Hospital, Athens
  • UHHS-Chagrin Highlands Medical Center, Beachwood
  • и још 37
Тражи се учесник
Узраст од 35 до 50 · Жене · Ажурирано 6. 11. 2026. · NCT04251052

The Vanguard Study: Testing a New Way to Screen for Cancer

  • Louis Stokes Cleveland VA Medical Center, Cleveland
Тражи се учесникЗдраве особе су добродошле
Узраст од 45 до 75 · Оба пола · Ажурирано 6. 11. 2026. · NCT06995898

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

  • Cleveland Clinic Foundation, Cleveland
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Жене · Ажурирано 5. 11. 2026. · NCT05051722

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

  • University Hospitals Cleveland Medical Center, Cleveland
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06465069

A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer

  • Miami Valley Hospital South, Centerville
  • University of Cincinnati Medical Center, Cincinnati
  • Oncology Hematology Care Inc, Cincinnati
  • и још 7
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT07213804

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  • Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute, Columbus
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT05579366

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

  • The Ohio State University (OSU) Wexner Medical Center, Columbus
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06400472

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

  • Cleveland Clinic - Oncology Department, Cleveland
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 4. 11. 2026. · NCT06760819

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

  • The Christ Hospital Physicians - Mt. Auburn, Cincinnati
  • Ohio State University CRS, Columbus
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT06303505

A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer

  • Site 0147 - Trihealth Cancer Institute - Harold and Eugen, Cincinnati
  • Site 0243 - Mark H Zangmeister Cancer Center, Columbus
  • Site 0214-Ohio State University Comprehensive Cancer Center, Hilliard
Тражи се учесникФаза 2
Узраст 18 и старији · Жене · Ажурирано 30. 10. 2026. · NCT05128825

Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring

  • Cleveland Clinic Mercy Hospital, Canton
  • University Hospitals Seidman Cancer Center, Cleveland
  • Tri-County Hematology & Oncology Associates, Inc., Massillon
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 30. 10. 2026. · NCT05974150

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

  • Cleveland Clinic Taussig Cancer Institute, Cleveland
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 29. 10. 2026. · NCT06774963

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

  • UH Cleveland Medical Center, Cleveland
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT07109726

Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)

  • Miami Valley Hospital South, Centerville
Тражи се учесникФаза 3
Узраст 18 и старији · Жене · Ажурирано 28. 10. 2026. · NCT06819007

Lead-212 PSV359 Therapy for Patients With Solid Tumors

  • Cleveland Clinic, Cleveland
  • Ohio State University, Columbus
Тражи се учесникФаза 1/2
Узраст од 18 до 90 · Оба пола · Ажурирано 28. 10. 2026. · NCT06710756

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

  • Ohio State University Wexner Medical Center, Hilliard
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT06161025

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

  • The Ohio State University Comprehensive Cancer Center, Columbus
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 26. 10. 2026. · NCT04981119

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

  • Oncology Hematology Care Primary, Cincinnati
  • Taylor Cancer Research Center, Maumee
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 22. 10. 2026. · NCT04657068

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

  • Metrohealth Medical Center - Cleveland /ID# 276664, Cleveland
  • Cleveland Clinic - Cleveland /ID# 276133, Cleveland
  • Cleveland Clinic - Cleveland /ID# 278273, Cleveland
  • и још 3
Тражи се учесникФаза 2
Узраст 18 и старији · Жене · Ажурирано 20. 10. 2026. · NCT06890338

Torvutatug Samrotecan With or Without Bevacizumab as Maintenance Treatment of Platinum-sensitive Relapsed Epithelial Ovarian Cancer

  • Research Site, Cleveland
  • Research Site, Cleveland
  • Research Site, Mayfield Heights
Тражи се учесникФаза 3
Узраст 18 и старији · Жене · Ажурирано 16. 10. 2026. · NCT07816666

A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

  • Jamescare Gynecologic Oncology At Mill Run /ID# 277951, Hilliard
Тражи се учесникФаза 2
Узраст 18 и старији · Жене · Ажурирано 13. 10. 2026. · NCT07059845

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

  • The Ohio State University, Columbus
Тражи се учесникФаза 1
Узраст 15 и старији · Оба пола · Ажурирано 9. 10. 2026. · NCT06276491

Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy

  • Miami Valley Hospital South, Centerville
  • Zangmeister Cancer Center, Columbus
Тражи се учесникФаза 3
Узраст 18 и старији · Жене · Ажурирано 6. 10. 2026. · NCT07225270

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

  • Research Site, Columbus
Тражи се учесникФаза 1/2
Узраст од 18 до 130 · Оба пола · Ажурирано 5. 10. 2026. · NCT05797168

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

  • The Cleveland Clinic Taussig Cancer Center, Cleveland
Тражи се учесникФаза 1/2
Узраст 12 и старији · Оба пола · Ажурирано 2. 10. 2026. · NCT04585750

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

  • University of Cincinnati Medical Center. /ID# 278925, Cincinnati
  • University Hospitals Cleveland Medical Center /ID# 279601, Cleveland
Тражи се учесникФаза 2
Узраст 18 и старији · Жене · Ажурирано 1. 10. 2026. · NCT07024784

A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors

  • Site 06, Maumee
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 30. 9. 2026. · NCT07814248

Study of AVZO-021 in Patients With Advanced Solid Tumors

  • Avenzo Therapeutics Recruiting Site, Cleveland
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 28. 9. 2026. · NCT05867251

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

  • The Ohio State University Wexner Medical Center, Columbus
Тражи се учесникФаза 1/2
Узраст 18 и старији · Жене · Ажурирано 25. 9. 2026. · NCT03564340

DESTINY-PANTUMOUR04

  • Research Site, Canton
  • Research Site, Maumee
Тражи се учесникОпсервациона студија
Узраст од 18 до 130 · Оба пола · Ажурирано 25. 9. 2026. · NCT07124000

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

  • The Ohio State University Wexner Medical Center, Columbus
Тражи се учесникФаза 1/2
Узраст 18 и старији · Жене · Ажурирано 24. 9. 2026. · NCT04590326

Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

  • Research Site, Cincinnati
  • Research Site, Columbus
Тражи се учесникФаза 2
Узраст од 18 до 130 · Оба пола · Ажурирано 23. 9. 2026. · NCT05489211

Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.